Literature DB >> 30790082

Body composition analysis in patients with myotonic dystrophy types 1 and 2.

Stojan Peric1, Ivo Bozovic1, Tanja Nisic2, Marija Banovic1, Milorad Vujnic3, Tamara Svabic1, Jovan Pesovic4, Marija Brankovic1, Ivana Basta1, Milena Jankovic1, Dusanka Savic-Pavicevic4, Vidosava Rakocevic-Stojanovic5.   

Abstract

INTRODUCTION: To date, there are only several reports on body composition in myotonic dystrophy type 1 (DM1) and there are no data for myotonic dystrophy type 2 (DM2). The aim was to analyze body composition of patients with DM1 and DM2, and its association with socio-demographic and clinical features of the diseases.
METHODS: There were no statistical differences in sociodemographic features between 20 DM1 patients and 12 DM2 patients. Body composition was assessed by DEXA (dual-energy x-ray absorptiometry). A three-compartment model was used: bone mineral content (BMC), fat mass (FM), and lean tissue mass (LTM).
RESULTS: Patients with DM1 and DM2 had similar total body mass (TBM), BMC, FM, and LTM. Patients with DM1 had higher trunk-limb fat index (TLFI) in comparison to DM2 patients which indicates visceral fat deposition in DM1 (1.16 ± 0.32 for DM1 vs. 0.87 ± 0.23 for DM2, p < 0.05). Right ribs bone mineral density was lower in DM2 group (0.68 ± 0.07 g/cm2 vs. 0.61 ± 0.09 g/cm2, p < 0.05). Higher percentage of FM in legs showed correlation with lower strength of the upper leg muscles in DM1 (ρ = - 0.47, p < 0.05). Higher muscle strength in DM2 patients was in correlation with higher bone mineral density (ρ = + 0.62, p < 0.05 for upper arm muscles, ρ = + 0.87, p < 0.01 for lower arm muscles, ρ = + 0.72, p < 0.05 for lower leg muscles).
CONCLUSION: DM1 patients had visceral obesity, and percentage of FM correlated with a degree of muscle weakness in upper legs. In DM2 patients, degree of muscle weakness was in correlation with higher FM index and lower bone mineral density.

Entities:  

Keywords:  Body composition; Bone mineral density; Muscle weakness; Myotonic dystrophy type 1; Myotonic dystrophy type 2; Visceral obesity

Mesh:

Year:  2019        PMID: 30790082     DOI: 10.1007/s10072-019-03763-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  4 in total

1.  Rare Neurologic Diseases and Neurological Sciences: a report for the celebration of the 2020 Rare Diseases Day.

Authors:  Antonio Federico
Journal:  Neurol Sci       Date:  2020-03       Impact factor: 3.307

2.  Myotonic dystrophy type 2: the 2020 update.

Authors:  Giovanni Meola
Journal:  Acta Myol       Date:  2020-12-01

3.  Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia.

Authors:  Fabian Hofmeister; Lisa Baber; Uta Ferrari; Stefan Hintze; Stefanie Jarmusch; Sabine Krause; Peter Meinke; Stefan Mehaffey; Carl Neuerburg; Fabiana Tangenelli; Benedikt Schoser; Michael Drey
Journal:  BMC Neurol       Date:  2021-06-25       Impact factor: 2.474

4.  Myotonic dystrophy type 1 as a major risk factor for severe COVID-19?

Authors:  Sebastiaan Dhont; Rutger Callens; Dieter Stevens; Fre Bauters; Jan L De Bleecker; Eric Derom; Eva Van Braeckel
Journal:  Acta Neurol Belg       Date:  2020-10-14       Impact factor: 2.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.